An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease

References

• Tiso M, Schechter AN, Jourd’heuil D. Nitrate reduction to nitrite, nitric oxide and ammonia by gut bacteria under physiological conditions. PLoS One. 2015;10(3):e0119712.
   PubMed Web of Science ®Google Scholar
• Nurjhan N, Bucci A, Perriello G, et al. Glutamine: a major gluconeogenic precursor and vehicle for interorgan carbon transport in man. J Clin Invest. 1995;95(1):272–277.
   PubMed Web of Science ®Google Scholar
• Biolo G, Zorat F, Antonione R, et al. Muscle glutamine depletion in the intensive care unit. Int J Biochem Cell Biol. 2005;37(10):2169–2179.
   PubMed Web of Science ®Google Scholar
• Watford M, Smith EM. Distribution of hepatic glutaminase activity and mRNA in perivenous and periportal rat hepatocytes. Biochem J. 1990;267(1):265–267.
   PubMed Web of Science ®Google Scholar
• Hankard RG, Haymond MW, Darmaun D. Role of glutamine as a glucose precursor in fasting humans. Diabetes. 1997;46(10):1535–1541.
   PubMed Web of Science ®Google Scholar
• Perriello G, Nurjhan N, Stumvoll M, et al. Regulation of gluconeogenesis by glutamine in normal postabsorptive humans. Am J Physiol. 1997;272(3 Pt 1):E437–E445.
   PubMed Web of Science ®Google Scholar
• Stipanuk MH, Ueki I. Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur. J Inherit Metab Dis. 2011;34(1):17–32.
   PubMed Web of Science ®Google Scholar
• Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87–105.
   PubMed Web of Science ®Google Scholar
• Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr. 2003;162(6):410–416.
   PubMed Web of Science ®Google Scholar
• Picca S, Dionisi-Vici C, Abeni D, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol. 2001;16(11):862–867.
   PubMed Web of Science ®Google Scholar
• Lewis HB. Studies in the synthesis of hippuric acid in the animal organims: II. The synthesis and rate of elimination of hippuruc acid after benzoate ingestion in man. J Biol Chem. 1914;18:2.
   Google Scholar
• Sherwin C, Kennard K. Toxicity of phenylacetic acid. J Biol Chem. 1919;40:5.
   Google Scholar
• Batshaw ML, Brusilow S, Waber L, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med. 1982;306(23):1387–1392.
   PubMed Web of Science ®Google Scholar
• Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science. 1980;207(4431):659–661.
   PubMed Web of Science ®Google Scholar
• Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991;29(2):147–150.
   PubMed Web of Science ®Google Scholar
• Bridges JW, French MR, Smith RL, et al. The fate of benzoic acid in various species. Biochem J. 1970;118(1):47–51.
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979;2(8140):452–454.
   PubMed Web of Science ®Google Scholar
• Webster LT, Siddiqui UA, Lucas SV, et al. Identification of separate acyl- CoA: glycineand acyl-CoA:L-glutamine N-acyltransferase activities in mitochondrial fractions from liver of rhesus monkey and man. J Biol Chem. 1976;251(11):3352–3358.
   PubMed Web of Science ®Google Scholar
• Kasumov T, Brunengraber LL, Comte B, et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab Dispos. 2004;32(1):10–19.
   PubMed Web of Science ®Google Scholar
• Comte B, Kasumov T, Pierce BA, et al. Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. J Mass Spectrom. 2002;37(6):581–590.
   PubMed Web of Science ®Google Scholar
• Mokhtarani M, Diaz GA, Rhead W, et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab. 2012;107(3):308–314.
   PubMed Web of Science ®Google Scholar
• Summar ML, Dasouki MJ, Schofield PJ, et al. Physical and linkage mapping of human carbamyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35. Cytogenet Cell Genet. 1995;71(3):266–267.
   PubMedGoogle Scholar
• Choi J-H, Lee BH, Kim JH, et al. Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency. J Hum Genet. 2015;60(9):501–507.
   PubMed Web of Science ®Google Scholar
• Engel K, Höhne W, Häberle J. Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat. 2009;30(3):300–307.
   PubMed Web of Science ®Google Scholar
• Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet. 2011;157C(1):45–53.
   PubMed Web of Science ®Google Scholar
• Sin, Y.Y., Baron, G., Schulze, A. et al. Arginase-1 deficiency. J Mol Med (Berl). 2015;93(12):1287–1296.
   PubMed Web of Science ®Google Scholar
• Brusilow SW, Horwich AL. Urea cycle enzymes. In: The metabolic & molecular bases of inherited disease. C.R. Driver, A.L. Beaded, W.S. Sly and D. Valle (eds). New York (NY): McGraw-Hill; 2001. p. 1909–1963.
   Google Scholar
• Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002;7(1):27–35.
   PubMedGoogle Scholar
• Haberle, J., Boddaert, N, Burlina, A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
   PubMed Web of Science ®Google Scholar
• Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–180.
   PubMed Web of Science ®Google Scholar
• Nassogne MC, Héron B, Touati G, et al. Urea cycle defects: management and outcome. J Inherit Metab Dis. 2005;28(3):407–414.
   PubMed Web of Science ®Google Scholar
• Msall M, Batshaw ML, Suss R, et al. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984;310(23):1500–1505.
   PubMed Web of Science ®Google Scholar
• Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. J Pediatr. 2001;138(1 Suppl):SS56-1.
   Web of Science ®Google Scholar
• Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127–170.
   PubMedGoogle Scholar
• The Urea Cycle Disorders Conference Group. Urea Cycle Disorders Conference, g., Consensus statement from a conference for the management of patients with urea cycle disorders. J Pediatr. 2001;138(1 Suppl):S1–S5.
   PubMed Web of Science ®Google Scholar
• Lefkowitch JH. The pathology of acute liver failure. Adv Anat Pathol. 2016;23(3):144–158.
   PubMed Web of Science ®Google Scholar
• Ytrebø LM, Kristiansen RG, Maehre H, et al. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology. 2009;50(1):165–174.
   PubMed Web of Science ®Google Scholar
• Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med. 2016;8(323): 323rv1.
   PubMed Web of Science ®Google Scholar
• Pacana T, Cazanave S, Verdianelli A, et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One. 2015;10(8):e0136822.
   Web of Science ®Google Scholar
• Romero-Gomez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015;62(2):437–447.
   PubMed Web of Science ®Google Scholar
• Vierling, J.M., Mokhtarani, M., Brown, R. S et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(16):903–906.
   PubMed Web of Science ®Google Scholar
• Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition. 2015;31(1):14–20.
   PubMed Web of Science ®Google Scholar
• Maier KP, Talke H, Gerok W. Activities of urea-cycle enzymes in chronic liver disease. Klin Wochenschr. 1979;57(13):661–665.
   PubMedGoogle Scholar
• Romero-Gómez M, Jover M, Del Campo JA, et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med. 2010;153(5):281–288.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59(3):1073–1083.
   PubMed Web of Science ®Google Scholar
• Misel ML, Gish RG, Patton H, et al. Sodium benzoate for treatment of hepatic encephalopathy. Gastroenterol Hepatol (N Y). 2013;9(4):219–227.
   PubMedGoogle Scholar
• Jalan R, Wright G, Davies NA, et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses. 2007;69(5):1064–1069.
   PubMed Web of Science ®Google Scholar
• Franco OE, Onishi T, Umeda Y, et al. Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines. Anticancer Res. 2003;23(2B):1637–1642.
   PubMed Web of Science ®Google Scholar
• Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 1992;52(7):1988–1992.
   PubMed Web of Science ®Google Scholar
• Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res. 1996;2(2):379–387.
   PubMed Web of Science ®Google Scholar
• Huang Y, Horvath CM, Waxman S. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. Cancer Res. 2000;60(12):3200–3206.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Baker SD, Grossman SA, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol. 2005;7(2):177–182.
   PubMed Web of Science ®Google Scholar
• Camacho LH, Olson J, Tong WP, et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs. 2007;25(2):131–138.
   PubMed Web of Science ®Google Scholar
• Baker MJ, Brem S, Daniels S, et al. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol. 2002;59(3):239–242.
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol. 1999;17(3):984–990.
   PubMed Web of Science ®Google Scholar
• Kusaczuk M, Krętowski R, Bartoszewicz M, et al. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line. Tumour Biol. 2016;37(1):931–942.
   PubMed Web of Science ®Google Scholar
• Baffy G. Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention. J Clin Transl Hepatol. 2013;1(2):131–137.
   PubMedGoogle Scholar
• Tsunedomi R, Iizuka N, Harada S, et al. Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression. Int J Oncol. 2013;42(4):1159–1166.
   PubMed Web of Science ®Google Scholar
• Svechnikova I, Gray SG, Kundrotiene J, et al. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol. 2003;22(3):579–588.
   PubMed Web of Science ®Google Scholar
• Lu Y-S, Kashida Y, Kulp SK, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 2007;46(4):1119–1130.
   PubMed Web of Science ®Google Scholar
• Lu Y-S, Chou C-H, Tzen K-Y, et al. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;83(2):e181–9.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Furumai R, Nishiyama M, et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001;48 Suppl 1(Suppl 1):S20–S26.
   PubMed Web of Science ®Google Scholar
• Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol. 2003;3(4):338–343.
   PubMed Web of Science ®Google Scholar
• Shapiro DJ, Livezey M, Yu L, et al. Anticipatory UPR activation: a protective pathway and target in cancer. Trends Endocrinol Metab. 2016;27:731–741.
   PubMed Web of Science ®Google Scholar
• Basseri S, Lhoták S, Sharma AM, et al. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. J Lipid Res. 2009;50(12):2486–2501.
   PubMed Web of Science ®Google Scholar
• Longo M, Spinelli R, D’Esposito V, et al. Pathologic endoplasmic reticulum stress induced by glucotoxic insults inhibits adipocyte differentiation and induces an inflammatory phenotype. Biochim Biophys Acta. 2016;1863(6 Pt A):1146–1156.
   PubMed Web of Science ®Google Scholar
• Kim D-S, Li B, Rhew KY, et al. The regulatory mechanism of 4-phenylbutyric acid against ER stress-induced autophagy in human gingival fibroblasts. Arch Pharm Res. 2012;35(7):1269–1278.
   PubMed Web of Science ®Google Scholar
• Mahadevan NR, Rodvold J, Almanza G, et al. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-kappaB-dependent manner. BMC Cancer. 2011;11:229.
   PubMed Web of Science ®Google Scholar
• Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:1–15.
   Web of Science ®Google Scholar
• Xiu F, Catapano M, Diao L, et al. Prolonged endoplasmic reticulum-stressed hepatocytes drive an alternative macrophage polarization. Shock. 2015;44(1):44–51.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Raina PN, Ramakrishnan CV. Comparative metabolic studies on normal and neoplastic rat liver. 3. changes in the composition of the culture medium with regard to arginine, glutamine, glutamic acid and alanine during cultivation of normal, neoplastic, newborn and regenerating liver. Oncology. 1964;18:9–13.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532.
   PubMed Web of Science ®Google Scholar
• Matés JM, Segura JA, Martín-Rufián M, et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2013;13(4):514–534.
   PubMed Web of Science ®Google Scholar
• Yuneva MO, Fan TWM, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–170.
   PubMed Web of Science ®Google Scholar
• Yu D, Shi X, Meng G, et al. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget. 2015;6(10):7619–7631. .
   PubMed Web of Science ®Google Scholar
• Lu P, Ma D, Chen Y, et al. L-glutamine provides acid resistance for Escherichia coli through enzymatic release of ammonia. Cell Res. 2013;23(5):635–644.
   PubMed Web of Science ®Google Scholar
• Ko KS, Tomasi ML, Iglesias-Ara A, et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology. 2010;52(6):2096–2108.
   PubMed Web of Science ®Google Scholar
• Martínez-Chantar ML, Vázquez-Chantada M, Ariz U, et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology. 2008;47(4):1191–1199.
   PubMed Web of Science ®Google Scholar
• Bode BP, Fuchs BC, Hurley BP, et al. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol. 2002;283(5):G1062–73.
   PubMed Web of Science ®Google Scholar
• Wu C, Roberts EH, Bauer JM. Enzymes related to glutamine metabolism in tumor-bearing rats. Cancer Res. 1965;25:677–684.
   PubMed Web of Science ®Google Scholar
• Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr. 2001;131(9 Suppl):2515S-22S; discussion 2523S-4S.
   Web of Science ®Google Scholar
• Bode JG, Peters-Regehr T, Kubitz R, et al. Expression of glutamine synthetase in macrophages. J Histochem Cytochem. 2000;48(3):415–422.
   PubMed Web of Science ®Google Scholar
• Tardito S, Chiu M, Uggeri J, et al. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets. 2011;11(8):929–943.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Sasayama T, Kohmura E. Targeting glutaminase and mTOR. Oncotarget. 2015;6(29):26544–26545.
   PubMed Web of Science ®Google Scholar
• Jones JG, Garcia P, Barosa C, et al. Hepatic anaplerotic outflow fluxes are redirected from gluconeogenesis to lactate synthesis in patients with Type 1a glycogen storage disease. Metab Eng. 2009;11(3):155–162.
   PubMed Web of Science ®Google Scholar
• Jones JG, Garcia P, Barosa C, et al. Quantification of hepatic transaldolase exchange activity and its effects on tracer measurements of indirect pathway flux in humans. Magn Reson Med. 2008;59(2):423–429.
   PubMed Web of Science ®Google Scholar
• Delgado TC, Silva C, Fernandes I, et al. Sources of hepatic glycogen synthesis during an oral glucose tolerance test: effect of transaldolase exchange on flux estimates. Magn Reson Med. 2009;62(5):1120–1128.
   PubMed Web of Science ®Google Scholar
• Magnusson I, Schumann WC, Bartsch GE, et al. Noninvasive tracing of Krebs cycle metabolism in liver. J Biol Chem. 1991;266(11):6975–6984.
   PubMed Web of Science ®Google Scholar
• Yang D, Previs SF, Fernandez CA, et al. Noninvasive probing of citric acid cycle intermediates in primate liver with phenylacetylglutamine. Am J Physiol. 1996;270(5 Pt 1):E882–9.
   PubMed Web of Science ®Google Scholar
• Sunny NE, Parks EJ, Browning JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14(6):804–810.
   PubMed Web of Science ®Google Scholar
• Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656–670.
   PubMed Web of Science ®Google Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–105.
   PubMed Web of Science ®Google Scholar
• Cabella C, Karlsson M, Canapè C, et al. In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-(13)C]glutamine. J Magn Reson. 2013;232:45–52.
   PubMed Web of Science ®Google Scholar
• Gallagher FA, Kettunen MI, Day SE, et al. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med. 2008;60(2):253–257.
   PubMed Web of Science ®Google Scholar
• Barosa C, Almeida M, Caldeira MM, et al. Contribution of proteolytic and metabolic sources to hepatic glutamine by (2)H NMR analysis of urinary phenylacetylglutamine (2)H-enrichment from (2)H(2)O. Metab Eng. 2010;12(1):53–61.
   PubMed Web of Science ®Google Scholar
• Ji Won Kim SHR, Kim S, Lee HW, et al. Pattern recognition analysis for hepatotoxicity induced by acetaminophen using plasma and urinary 1H NMR-based metabolomics in humans. Anal Chem. 2013;85(23):8.
   Web of Science ®Google Scholar
• Ammonul. Drug Approval Package. [cited 2016 Oct 05]. Available from:http://www.accessdat.fda.gov
   Google Scholar
• Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138(1 Suppl):SS46-5.
   Web of Science ®Google Scholar
• Shneider BL, Vockley J. Possible phenylacetate hepatotoxicity during 4-phenylbutyrate therapy of byler disease. J Pediatr Gastroenterol Nutr. 2016;62(3): 424-428.
   PubMed Web of Science ®Google Scholar
• Scaglia F, Carter S, O’Brien WE, et al. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab. 2004;81(Suppl 1):S79–85.
   PubMed Web of Science ®Google Scholar
• Burrage LC, Jain M, Gandolfo L, et al. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metab. 2014;113(1–2):131–135.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Dietary guidelines for Americans. 2005. Available from: http://www.health.gov/DietaryGuidelines/dga2005/document/default.htm.
   Google Scholar
• Oishi K, Diaz G. Glycerol phenylbutyrate for the chronic management of urea cycle disorders. Expert Rev Endocrinol Metab. 2014;9(5):427–434.
   PubMedGoogle Scholar
• Das AM, Illsinger S, Hartmann H, et al. Prenatal benzoate treatment in urea cycle defects. Arch Dis Child Fetal Neonatal Ed. 2009;94(3):F216–F217.
   PubMed Web of Science ®Google Scholar
• Burrage LC, Nagamani SCS, Campeau PM, et al. Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders. Hum Mol Genet. 2014;23(R1):R1–R8.
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Lanpher B, Erez A, et al. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet. 2011;20(4):631–640.
   PubMed Web of Science ®Google Scholar
• Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. 2002;6(1):119–126.
   PubMed Web of Science ®Google Scholar
• Guffon N, Kibleur Y, Copalu W, et al. Developing a new formulation of sodium phenylbutyrate. Arch Dis Child. 2012;97(12):1081–1085.
   PubMed Web of Science ®Google Scholar
• Kibleur Y, Dobbelaere D, Barth M, et al. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane((R)) (Sodium Phenylbutyrate) taste-masked granules. Paediatr Drugs. 2014;16(5):407–415.
   PubMed Web of Science ®Google Scholar
• Kibleur Y, Guffon N. Long-term follow-up on a cohort Temporary Utilization Authorization (ATU) survey of patients treated with pheburane (Sodium Phenylbutyrate) taste-masked granules. Paediatr Drugs. 2016;18(2):139–144.
   PubMed Web of Science ®Google Scholar